Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership

Core Insights - Kane Biotech Inc. is expanding its U.S. commercialization strategy for its advanced wound care portfolio, including the revyve Antimicrobial Wound Gel, through partnerships and a new sales team [1][6]. Group 1: Partnerships and Agreements - Kane Biotech has signed a distribution agreement with Marathon Medical Corporation, a Service-Disabled Veteran-Owned Small Business, to facilitate entry into the U.S. Veterans Affairs, Department of Defense, and Indian Health Services markets [2][3]. - The partnership with Marathon Medical provides Kane access to established government purchasing pathways, streamlining procurement and logistics for its wound care products [3]. Group 2: Sales Strategy - Kane is building a contract-based sales team across the U.S. to enhance its national sales foundation and increase brand presence [4][5]. - The expansion of the sales team is part of Kane's broader strategy to establish a scalable, multi-channel U.S. distribution infrastructure [5]. Group 3: Product Information - The revyve Antimicrobial Wound Gel and its spray format have received FDA 510(k) clearance and Health Canada approval, addressing biofilms and wound bacteria [7][9].